ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

ABCC5 facilitates the acquired resistance of sorafenib through the inhibition of SLC7A11-induced ferroptosis in hepatocellular carcinoma

Huang, Wenbin; Chen, Kunling; Lu, Yishi; Zhang, Donghui; Cheng, Yuan; Li, Liuran; Huang, Weimei; He, Guolin; Liao, Hangyu; Cai, Lei; Tang, Yujun; Zhao, Liang*; Pan, Mingxin广州医学院; 南方医科大学
Neoplasia2021-12DOI: 10.1016/j.neo.2021.11.002
59被引7阅读
引用收藏
分享

摘要

Sorafenib is a first-line molecular-target drug for advanced hepatocellular carcinoma (HCC), and reducing sorafenib resistance is an important issue to be resolved for the clinical treatment of HCC. In the current study, we identified that ABCC5 is a critical regulator and a promising therapeutic target of acquired sorafenib resistance in human hepatocellular carcinoma cells. The expression of ABCC5 was dramatically induced in sorafenib-resistant HCC cells and was remarkably associated with poor clinical prognoses. The down-regulation of ABCC5 expression could significantly reduce the resistance of sorafenib to HCC cells. Importantly, activation of PI3K/AKT/NRF2 axis was essential for sorafenib to induce ABCC5 expression. ABCC5 increased intracellular glutathione (GSH) and attenuated lipid peroxidation accumulation by stabilizing SLC7A11 protein, which inhibited ferroptosis. Additionally, the inhibition of ABCC5 enhanced the anti-cancer activity of sorafenib in vitro and in vivo . These findings demonstrate a novel molecular mechanism of acquired sorafenib resistance and also suggest that ABCC5 is a new regulator of ferroptosis in HCC cells.

学科与关键词

关键词
Hepatocellular carcinomaSorafenibABCC5FerroptosisAcquired resistance
相关
加载中…
  • FXYD5 promotes sorafenib resistance through the Akt/mTOR signaling pathway in hepatocellular carcinoma
    Tan, Xiang-Peng; Xiong, Ben-Han; Zhang, Yuan-Xu; Wang, Shen-Li; Zuo, Qian*; Li, Jing*European Journal of Pharmacology, 2022, 931: 175186.被引 5
  • Downregulation of MCF2L Promoted the Ferroptosis of Hepatocellular Carcinoma Cells through PI3K/mTOR Pathway in a RhoA/Rac1 Dependent Manner
    Huang, Si-cong; Chen, Yi-mei; Hu, Ying-yu; Shi, Yong-jie; Xiao, Qi-wen; Li, Zhe; Kang, Jia-le; Zhou, Qiang; Shen, Gang*; Jia, Hong-yun*DISEASE MARKERS, 2022, 2022: 6138941.被引 3
  • Fe3+-binding transferrin nanovesicles encapsulating sorafenib induce ferroptosis in hepatocellular carcinoma
    Xiao, Youmei; Xu, Zhanxue; Cheng, Yuan; Huang, Rufan; Xie, Yuan; Tsai, Hsiang-i; Zha, Hualian; Xi, Lifang; Wang, Kai; Cheng, Xiaoli; Gao, Yanfeng; Zhang, Changhua*; Cheng, Fang*; Chen, Hongbo*BIOMATERIALS RESEARCH, 2023, 27(1): 63.被引 5
查看全部 →

发表信息

论文状态
公开发表
期刊
Neoplasia
发表日期
2021-12
卷期
第 23 卷, 第 12 期
页码
1227-1239
DOI
10.1016/j.neo.2021.11.002
语言
ENGLISH
成果收录
SCIE
资助标注
National Natural Science Foundation of China [82072627, 81972813]; Fork Ying Tung Education Foundation [161035]

作者

  • H

    Huang, Wenbin (第一作者)

    2 · southern med univ

  • C

    Chen, Kunling

    2 · southern med univ

查看全部 13 位作者收起作者
  • L

    Lu, Yishi

    southern med univ

  • Z

    Zhang, Donghui

    guangzhou med univ

  • C

    Cheng, Yuan

    2 · southern med univ

  • L

    Li, Liuran

    2 · southern med univ

  • H

    Huang, Weimei

    2 · southern med univ

  • H

    He, Guolin

    2 · southern med univ

  • L

    Liao, Hangyu

    2 · southern med univ

  • C

    Cai, Lei

    2 · southern med univ

  • T

    Tang, Yujun

    2 · southern med univ

  • Z

    Zhao, Liang (通讯)

    southern med univ

  • P

    Pan, Mingxin

    2 · southern med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417